menu search

Rolls-royce to cut up to 2,500 roles in latest efficiency drive

British engineering company Rolls-Royce said it would cut up to 2,500 roles as its new chief executive seeks to build a more efficient business, in th...

October 17, 2023, 2:19 am

British pound eyes uk employment release

UK releases employment data on Tuesday BoE’s Bailey says rate decisions will be tight The british pou...

October 17, 2023, 12:35 am

Gbp/usd gains momentum and climbs above 1.2200 ahead of uk inflation report

The british Pound (GBP) advances versus the US Dollar (USD) during the North American session, register...

October 16, 2023, 5:14 pm

Consolidated communications (cnsl) news: johnson fistel investigates proposed sale; is $4.70 a fair price?

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board mem...

October 16, 2023, 4:07 pm

Citigroup banker fired for lying about two-sandwich lunch expense loses wrongful dismissal lawsuit

A british judge ruled that the bank was entitled to sack Szabolcs Fekete for gross misconduct because h...

October 16, 2023, 3:13 pm

Trade gas: impact of geopolitics and reserves on prices

Trade Gas: Impact of Geopolitics and Reserves on Prices The interplay between geopolitical tensions, weather fluctuations, and energy reserves can sig...

October 16, 2023, 2:58 pm

British pound eyes uk employment release

UK releases employment data on Tuesday BoE’s Bailey says rate decisions will be tight The british pou...

October 16, 2023, 2:33 pm

Talisker initiates entry portal construction at the bralorne gold project

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in...

October 16, 2023, 11:44 am

Doubleview gold unveils assay results extending hat deposit's potential

Doubleview Gold Corp (TSX-V:DBG, OTCQB:DBLVF) reported significant assay results from three drill holes at the Hat deposit in northwest...

October 16, 2023, 10:54 am

Verses ai ceo & founder to participate in upcoming conferences

Lytham Partners Fall 2023 Investor Conference, Tuesday Oct 17th ThinkEquity 2023 Conference, Thursday Oct 19th in NYC VANCOUVER,...

October 16, 2023, 9:44 am

Consolidated communications holdings to be acquired by two private-equity firms

Consolidated Communications Holdings Inc. CNSL, -1.12% said Monday it agreed to be taken private by affiliates of Searchlight Capital Partners LP and<...

October 16, 2023, 8:24 am

Bat turn to rooibos tea in response to flavoured tobacco bans

British American Tobacco PLC (LSE:BATS) and other Big Tobacco players are tapping the tea market to counter European bans on flavoured heated tobacco...

October 16, 2023, 7:56 am

Gbp/usd restarts decrease, eur/gbp aims higher

GBP/USD started a fresh decline from the 1.2335 resistance zone. EUR/GBP is rising and might climb above the 0.8665 resistance. Important Takeaways fo...

October 16, 2023, 7:43 am

Astrazeneca's tagrisso-chemo combo given priority review in us

The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy has been been accepted and granted priority review by the U.S. Food and Drug...

October 16, 2023, 2:34 am

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm


Search within

Pages Search Results: